Louise Rodino-Klapac - 11 Mar 2026 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
President, R&D and Tech Ops
Signature
/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac
Issuer symbol
SRPT
Transactions as of
11 Mar 2026
Net transactions value
$0
Form type
4
Filing time
13 Mar 2026, 20:05:03 UTC
Previous filing
11 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rodino-Klapac Louise President, R&D and Tech Ops 215 FIRST STREET, SUITE 415, CAMBRIDGE /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac 13 Mar 2026 0001836218

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Tax liability -948 -0.42% $17.03* 225,323 11 Mar 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 10, 2025.